小剂量盐酸替罗非班辅助急性ST段抬高型心肌梗死行急诊PCI的安全性及疗效观察

Safety and Efficacy of Low-dose Tirofiban Hydrochloride in the Adjuvant Therapy of Acute ST-segment Elevation Myocardial Infarction Undergoing Emergency PCI

目的:探讨小剂量盐酸替罗非班辅助急性ST段抬高型心肌梗死(STEMI)行急诊PCI的安全性及疗效分析。方法:以本院116例STEMI患者为研究对象,根据计算机生成的随机数字表,将患者分为观察组(58例)、对照组(58例)。观察组予以0.12μg/(kg·min)盐酸替罗非班,对照组予以0.15μg/(kg·min),用药36 h。评估术后即刻前向TIMI血流分析疗效,统计干预期间血小板减少情况及主要的心血管不良事件。结果:两组PCI术后TIMI血流分级比较,差异无统计学意义(P>0.05)。干预后观察组的LVEF、E/A数值均高于对照组,差异具有统计学意义(P<0.05)。干预期间观察组不良反应总发生率低于对照组,差异具有统计学意义(P<0.05)。结论:小剂量盐酸替罗非班有助于STEMI患者PCI术后心功能恢复,且减少不良事件,安全性较好。

Objective:To investigate the safety and efficacy of low-dose tirofiban hydrochloride in the adjuvant therapy of acute ST-segment-elevation myocardial infarction(STEMI)undergoing emergency PCI.Methods:116 STEMI patients in the hospital were taken as the research subjects.According to the computer-generated random number table method,the patients were divided into the observation group(58 cases)and the control group(58 cases).The observation group was given 0.12μg/kg·min tirofiban hydrochloride while the control group was given 0.15μg/kg·min tirofiban hydrochloride,and they were treated for 36h.The efficacy was analyzed by immediate postoperative forward TIMI blood flow,and the thrombocytopenia and major cardiovascular adverse events were counted during intervention.Results:There was no significant difference in the TIMI blood flow classification between the two groups after PCI(P>0.05).After intervention,the LVEF and E/A values of the observation group were were higher than those of the control group(P<0.05).During intervention,the total incidence rate in observation group was lower than that in control group(8.62%vs 24.14%)(P<0.05).Conclusion:Low-dose tirofiban hydrochloride can help the recovery of cardiac function and reduce adverse events in patients with STEMI after PCI,with good safety.